Cardioblate BP in Europe
This article was originally published in The Gray Sheet
Executive Summary
Medtronic surgical ablation system earns CE mark for treatment of atrial fibrillation, company announces during European Association of Thoracic Surgeons sessions Oct. 14 in Vienna. The system features a transmurality feedback mechanism that alerts surgeons when the ablation line passes all the way through the tissue, the company notes. Medtronic earned FDA clearance for the device in February 2002 and plans to complete a trial in support of an AF indication in 2004 (1"The Gray Sheet" Aug. 11, 2003, In Brief)...
You may also be interested in...
Medtronic next-gen Cardioblate BP cleared by FDA
Firm plans to commence a clinical trial to examine device effectiveness in treating chronic atrial fibrillation this autumn, Medtronic states Aug. 6, following July clearance of the bipolar radiofrequency ablation system for surgical procedures. The more specific indication, for which the firm plans to seek agency go-ahead, following trial completion in 2004, would allow Medtronic to market the device specifically for AF. The single-electrode, first-generation device was first cleared in February 2002 (1'The Gray Sheet" Feb. 4, 2002, In Brief)...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.